Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 11/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28198189 | 0.95 | FKBP1A (0.57) | FKBP1AMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL24661351 | 0.88 | FKBP1A (0.65) | FKBP1AMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL5485208 | 0.87 | FKBP1A (0.63) | FKBP1AMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL13373975 | 0.87 | FKBP1A (0.63) | FKBP1AMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL20526457 | 0.86 | FKBP1A (0.56) | FKBP1A | |
| SCHEMBL6541395 | 0.85 | FKBP1A (0.62) | FKBP1AMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL7395734 | 0.84 | FKBP1A (0.68) | FKBP1AMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL7310339 | 0.84 | FKBP1A (0.60) | FKBP1AMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL11187944 | 0.83 | FKBP1A (0.59) | FKBP1AMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL5966031 | 0.83 | FKBP1A (0.67) | FKBP1AMEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1723121-B1 | 1,4-DIARYL-DIHYDROPYRIMIDIN-2-ONES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | Bayer Pharma AG (DE) | 2012-07-25 | — | — | EP | disclosed |
| US-8101615-B2 | Chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction, heart failure | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-24 | — | — | US | disclosed |
| US-20080064704-A1 | 1,4-Diaryl-Dihydropyrimidin-2-Ones and Their Use as Human Neutrophil Elastase Inhibitors | BAYER HEALTHCARE AG (DE) | 2008-03-13 | — | — | US | disclosed |
| EP-1723121-A1 | 1,4-DIARYL-DIHYDROPYRIMIDIN-2-ONES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | Bayer HealthCare AG (DE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005082864-A1 | 1,4-DIARYL-DIHYDROPYRIMIDIN-2-ONES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064704-A1 | 1,4-Diaryl-Dihydropyrimidin-2-Ones and Their Use as Human Neutrophil Elastase Inhibitors | SERPINB1, ELANE, MPO | FKBP1A 1691/4885MEN1 4156/4885KMT2A 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.